UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Post-Transplant Lymphoproliferative Disorders

2nd Edition 2021, 2021

Volltextzugriff (PDF)

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

Trials, 2021-11, Vol.22 (1), p.765-765, Article 765

2021

Volltextzugriff (PDF)

Peri-operative ovarian cancer guidelines: major intra-operative and post-operative bleeding and thromboembolic events

International journal of gynecological cancer, 2022-12, Vol.32 (12), p.1621-1622

2022

Volltextzugriff (PDF)

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery

International journal of gynecological cancer, 2021-09, Vol.31 (9), p.1199-1206

2021

Volltextzugriff (PDF)

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

Clinical cancer research, 2011, Vol.17 (1), p.19-30

2011

Volltextzugriff (PDF)

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

Haematologica (Roma), 2023-10, Vol.108 (10), p.2814-2819

2023

Volltextzugriff (PDF)

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

HemaSphere, 2023-08, Vol.7 (S3), p.e8073255-n/a

2023

Volltextzugriff (PDF)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

HemaSphere, 2022-04, Vol.6 (4), p.e692-n/a

2022

Volltextzugriff (PDF)

Therapeutic options in post-transplant lymphoproliferative disorders

Therapeutic Advances in Hematology, 2011-12, Vol.2 (6), p.393-407

2011

Volltextzugriff (PDF)

Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten

Deutsche medizinische Wochenschrift, 2016-09, Vol.141 (20), p.1446-1450

2016

Volltextzugriff (PDF)

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

The New England journal of medicine, 2018-06, Vol.378 (25), p.2399-2410

2018

Volltextzugriff (PDF)

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry

Blood, 2019-11, Vol.134 (Supplement_1), p.65-65

2019

Volltextzugriff (PDF)

Demographics and treatment outcomes in patients with EBV + PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7530-7530

2022

Volltextzugriff (PDF)

Effectiveness and safety outcomes in patients with EBV + PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7521-7521

2023

Volltextzugriff (PDF)

Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV +) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study

Blood, 2021-11, Vol.138 (Supplement 1), p.2528-2528

2021

Volltextzugriff (PDF)

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Haematologica (Roma), 2007-02, Vol.92 (2), p.273-274

2007

Volltextzugriff (PDF)

Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8045-8045

2020

Volltextzugriff (PDF)

Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

Bone marrow transplantation (Basingstoke), 2021-09, Vol.56 (9), p.2118-2124

2021

Volltextzugriff (PDF)

The Impact of EBV upon the Tumor Microenvironment and Mutational Profile of Primary CNS Lymphoma in PTLD

Blood, 2017-12, Vol.130, p.2731-2731

2017

Volltextzugriff (PDF)

Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center

Leukemia & lymphoma, 2016-12, Vol.57 (12), p.2791-2803

2016

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(69)

Publikationsform

Sprache

Englisch
(77)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Humans
(24)
Female
(15)
Hematology
(15)
Rituximab
(14)
Male
(13)
Middle Aged
(13)
Adult
(12)
Epstein-Barr Virus
(12)
Oncology
(10)
Transplantation
(10)
Aged
(9)
Ebv
(9)
Ptld
(8)
Chemotherapy
(7)
Immunology
(7)
Treatment Outcome
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Immunosuppression
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Post-Transplant Lymphoproliferative Disorders

Peri-operative ovarian cancer guidelines: major intra-operative and post-operative bleeding and thromboembolic events

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Therapeutic options in post-transplant lymphoproliferative disorders

Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry

Demographics and treatment outcomes in patients with EBV + PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses

Effectiveness and safety outcomes in patients with EBV + PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe

Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV +) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study

Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

The Impact of EBV upon the Tumor Microenvironment and Mutational Profile of Primary CNS Lymphoma in PTLD

Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center

Suchergebnisse filtern